Anne Wojcicki
Showing 1–2 of 2 transcripts.
- Sequoia Capital38 min
23andMe ft. Anne Wojcicki - How a DNA startup took on the FDA and redefined health tech
Anne Wojcicki, Richard Scheller, Rolf Huerta
Founded by Anne Wojcicki to democratize genetic access, 23andMe rapidly expanded to over 14 million users before navigating a critical 2013 FDA mandate that forced a multi-year transition from an unregulated startup to a compliant healthcare entity. Following a 2019 market stall, the company acquired Lemonade Health to launch a full-stack consumer model while simultaneously leveraging its vast data to pivot into high-risk therapeutics, recently advancing its first investigational cancer antibody into Phase II trials. This strategic evolution transforms the organization from a direct-to-consumer ancestry provider into a leader in genomic-based drug discovery and personalized preventive care.
- Y Combinator28 min
Anne Wojcicki : How to Build the Future
Anne Wojcicki, William Brangham, Dr. Kathleen King
Anne Wojcijk founded 23andMe to democratize genomic data by shifting healthcare incentives from illness monetization to preventative health, despite initial skepticism from medical professionals regarding direct-to-consumer genetic testing. Overcoming early market volatility and a regulatory transition, the company now boasts a community of over five million customers and has secured FDA approvals to leverage its massive dataset for drug discovery and large-scale intervention studies. This persistent execution of a decade-long vision aims to eventually enable personalized longevity strategies by linking genetic profiles with environmental factors like diet and exercise.